MiNK Therapeutics (INKT) Short Interest Ratio & Short Volume → [FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (From Crypto 101 Media) (Ad) Free INKT Stock Alerts $1.04 0.00 (0.00%) (As of 05/16/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media MiNK Therapeutics Short Interest DataCurrent Short Volume87,500 sharesPrevious Short Volume48,500 sharesChange Vs. Previous Month+80.41%Dollar Volume Sold Short$86,625.00Short Interest Ratio / Days to Cover0.9Last Record DateApril 30, 2024Outstanding Shares34,700,000 sharesFloat Size9,950,000 sharesShort Percent of Float0.88%Today's Trading Volume76,498 sharesAverage Trading Volume143,326 sharesToday's Volume Vs. Average53% Short Selling MiNK Therapeutics ? Sign up to receive the latest short interest report for MiNK Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatINKT Short Interest Over TimeINKT Days to Cover Over TimeINKT Percentage of Float Shorted Over Time Ad Crypto 101 Media“Dollar Will Be Worth NOTHING” -MuskElon Musk just issued an urgent warning… Saying “The U.S. Dollar will be worth NOTHING…” As "stealth money printing" pushes the price of Bitcoin, Ethereum, XRP and crypto higher.Click here to claim your free seat ticket now. MiNK Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/202487,500 shares $86,625.00 +80.4%0.9%0.9 $0.99 4/15/202448,500 shares $44,062.25 +18.0%0.5%0.5 $0.91 3/31/202441,100 shares $37,331.13 -11.6%0.4%0.4 $0.91 3/15/202446,500 shares $41,594.25 +12.6%0.5%0.8 $0.89 2/29/202441,300 shares $38,049.69 -76.4%0.4%0.7 $0.92 2/15/2024175,100 shares $162,843.00 -7.6%1.8%3.4 $0.93 Get the Latest News and Ratings for INKT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for MiNK Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/31/2024189,400 shares $163,831.00 +8.3%2.0%3.8 $0.87 1/15/2024174,900 shares $172,976.10 -1.7%1.8%3.8 $0.99 12/31/2023178,000 shares $190,460.00 +237.8%1.9%4.6 $1.07 12/15/202352,700 shares $53,754.00 -66.3%0.6%1.2 $1.02 11/30/2023156,400 shares $164,220.00 +2.4%1.6%3.9 $1.05 11/15/2023152,700 shares $155,754.00 -19.7%1.6%3.4 $1.02 10/31/2023190,100 shares $193,902.00 +11.7%2.0%3.6 $1.02 10/15/2023170,200 shares $187,220.00 +6.7%1.8%3 $1.10 9/30/2023159,500 shares $175,450.00 -11.7%1.8%2.4 $1.10 9/15/2023180,600 shares $232,974.00 -7.7%1.9%2.5 $1.29 8/31/2023195,700 shares $283,765.00 -1.0%2.1%1.9 $1.45 8/15/2023197,600 shares $337,896.00 -31.4%2.0%1.8 $1.71 7/31/2023288,000 shares $538,560.00 +6.9%3.0%2.1 $1.87 7/15/2023269,500 shares $493,185.00 +1.7%2.8%1.4 $1.83 6/30/2023264,900 shares $556,290.00 +68.5%2.7%1.4 $2.10 6/15/2023157,200 shares $377,280.00 +2.0%1.6%0.9 $2.40 5/31/2023154,100 shares $271,216.00 -14.6%1.7%1.2 $1.76 5/15/2023180,500 shares $305,045.00 +70.4%1.9%1.5 $1.69 4/30/2023105,900 shares $189,561.00 +117.5%1.1%1.1 $1.79 4/15/202348,700 shares $107,627.00 +34.2%1.1%2.8 $2.21 3/31/202336,300 shares $68,788.50 -14.0%0.8%3.2 $1.90 3/15/202342,200 shares $84,822.00 +92.7%1.0%3.6 $2.01 2/28/202321,900 shares $44,457.00 -60.9%0.5%2.2 $2.03 2/15/202356,000 shares $112,560.00 -19.4%1.3%4.6 $2.01 1/31/202369,500 shares $159,155.00 -10.6%1.6%3.2 $2.29 1/15/202377,700 shares $183,372.00 -15.2%1.7%3.4 $2.36 12/30/202291,600 shares $239,076.00 -7.0%2.0%3.9 $2.61 12/15/202298,500 shares $217,685.00 -34.9%2.1%4 $2.21 11/30/2022151,400 shares $401,210.00 -7.4%3.3%5.2 $2.65 11/15/2022163,500 shares $501,667.05 +24.0%3.5%4.6 $3.07 10/31/2022131,900 shares $287,542.00 +3.2%2.8%0.3 $2.18 10/15/2022127,800 shares $241,542.00 -0.8%2.8%0.3 $1.89 9/30/2022128,800 shares $271,768.00 +25.1%2.8%0.3 $2.11 9/15/2022103,000 shares $269,860.00 -46.1%2.2%0.2 $2.62[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (Ad)Are you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. You see, while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls. Claim your free seat by clicking here now. INKT Short Interest - Frequently Asked Questions What is MiNK Therapeutics' current short interest? Short interest is the volume of MiNK Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 30th, investors have sold 87,500 shares of INKT short. 0.88% of MiNK Therapeutics' shares are currently sold short. Learn More on MiNK Therapeutics' current short interest. What is a good short interest ratio for MiNK Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. INKT shares currently have a short interest ratio of 1.0. Learn More on MiNK Therapeutics's short interest ratio. What is a good short interest percentage for MiNK Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.88% of MiNK Therapeutics' floating shares are currently sold short. Is MiNK Therapeutics' short interest increasing or decreasing? MiNK Therapeutics saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 87,500 shares, an increase of 80.4% from the previous total of 48,500 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is MiNK Therapeutics' float size? MiNK Therapeutics currently has issued a total of 34,700,000 shares. Some of MiNK Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. MiNK Therapeutics currently has a public float of 9,950,000 shares. How does MiNK Therapeutics' short interest compare to its competitors? 0.88% of MiNK Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to MiNK Therapeutics: Quince Therapeutics, Inc. (6.58%), Estrella Immunopharma, Inc. (0.12%), SAB Biotherapeutics, Inc. (0.30%), Cyclo Therapeutics, Inc. (0.35%), Achilles Therapeutics plc (0.06%), Pluri Inc. (0.97%), OKYO Pharma Limited (0.43%), Brainstorm Cell Therapeutics Inc. (3.07%), Dyadic International, Inc. (0.96%), Surrozen, Inc. (2.15%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short MiNK Therapeutics stock? Short selling INKT is an investing strategy that aims to generate trading profit from MiNK Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against MiNK Therapeutics? A short squeeze for MiNK Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of INKT, which in turn drives the price of the stock up even further. How often is MiNK Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including INKT, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: QNCX Short Interest ESLA Short Interest SABS Short Interest CYTH Short Interest ACHL Short Interest PLUR Short Interest OKYO Short Interest BCLI Short Interest DYAI Short Interest SRZN Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:INKT) was last updated on 5/17/2024 by MarketBeat.com Staff From Our Partners348 million Americans lives to END as we know it?The Oxford ClubCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceGold Set to EXPLODE!Gold Safe ExchangeInvest in the "Trojan Horse" of Alzheimer's TreatmentBehind the MarketsHow Biden has already won 2024Porter & CompanyA once-in-a-century investment opportunityStansberry ResearchCharles Payne Demystifies OptionsUnstoppable ProsperityBiden FINISHED On June 13th?Paradigm Press